



JAGSONPAL PHARMACEUTICALS LIMITED

**Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)**

**Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181**

May 24, 2024

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
--	---

Subject: Press Release – Jagsonpal Launches MemUp: India's First Bioidentical Hormone Replacement Therapy in a Single Pill

Dear Sir/ Madam,

In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of the Press Release issued by the Company titled “**Jagsonpal Launches MemUp: India's First Bioidentical Hormone Replacement Therapy in a Single Pill**”.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary & Compliance Officer

Encl.: A/a



Jagsonpal Launches *MemUp*: India's First Bioidentical Hormone Replacement Therapy in a Single Pill

Gurugram, Haryana, May 23, 2024: Jagsonpal, one of the leading pharmaceutical companies in women's health today announced the launch of *MemUp*, India's first hormone replacement therapy (HRT) featuring USFDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule. *MemUp* marks a significant advancement in women's healthcare, offering a ground-breaking solution for the management of vasomotor symptoms of menopause like hot flashes, night sweats and sleep issues.

Over 130 million Indian women are currently in menopause or approaching it. The average age at which Indian women experience menopause is 46.2 years. Despite its prevalence, awareness and understanding of menopause and its management remain limited. Several women struggle to seek support due to social stigma and the lack of healthcare options. *MemUp* is designed to specifically address this gap and support the urgent need for innovative and effective treatments. The unique combination mimics the body's natural hormones, providing a more balanced and natural approach to HRT. This innovative formulation not only simplifies the treatment regimen but also enhances patient compliance and outcomes. *MemUp* will be made available at retailers across the country and can be purchased on the submission of a valid prescription issued by a Registered Medical Practitioner.

"The launch of MemUp strengthens Jagsonpal's commitment to the gynaecological segment with one of the widest range of offering of products catering to various conditions and its successful management, stated Mr. Manish Gupta, Managing Director. He added that in the coming quarters, the Company will continue to bolster its presence with novel and customised formulations within the Gynaecological category."

The launch also marks a significant step in Jagsonpal's commitment to women's health, coinciding with the unveiling of the website, www.mysakhi.in. This website is a crucial part of Jagsonpal's Corporate Social Responsibility (CSR) initiative focused on improving the health and well-being of women at all stages of life, from adolescence through menopause.

Jagsonpal is also rolling out comprehensive women and family outreach programs to increase awareness about menopause, promote early diagnosis, and enhance management practices through various educational campaigns and support networks. Recognizing the diverse linguistic landscape of India, the content will be accessible in nine regional languages besides Hindi and English, ensuring that women across the country can benefit from the information and support provided, in their preferred language.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the Company has a proven track record of over 4 decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology and Orthopaedic segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in respective segments. It has created a strong niche for itself with 17 brands amongst Top 5 brands in the molecule category. It has an extensive pan-India presence through its strong sales team of 900+ professionals.

Infinity Holdings acquired a majority stake in the company and is a joint promoter of the company. The company is listed on the National Stock Exchange Limited (NSE) and Bombay Stock Exchange (BSE).

For more information, please visit: www.jagsonpal.com

Dr. Deepika Chhabra

Contact: medicalservices@jagsonpal.com, +91 124 4406710

Jagsonpal Pharmaceuticals Limited

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Corporate Office: 412-415 Nimai Tower, 3rd floor, Udyog Vihar Phase IV, Gurugram, Haryana – 122015